

Not for direct or indirect distribution in the United States of America,  
Canada, Australia or Japan

# CARMAT

PRESS RELEASE

## Success of CARMAT's IPO on the Alternext of NYSE Euronext Paris €15.5m raised

### Paris, 7 July 2010:

CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, today announces the success of its Initial Public Offering on the Alternext of NYSE Euronext Paris. This investor demand, which represents 1.1 times its initial size, is all the more noteworthy given that the placement, which was completed on 6 July 2010, was carried out under particularly difficult market conditions.

The Company thus decided:

- to set the price of its share issue on the Alternext of NYSE Euronext Paris at €18.75, which corresponds to the middle of the price bracket and to partially exercise the extension clause to the tune of 27,002 new shares; and
- to issue a total of 827,002 new shares, i.e. €15.5m.

The final allocation is as follows:

- Global Placement: 681,843 shares allocated to institutional investors (82.4% of the total number of shares offered);
- Open-Price Offer (the "OPO"): 145,159 shares allocated to the public (17.6% of the total number of shares offered).

Following the Offer, CARMAT's capital consists of 3,800,059 shares, with floating capital of 21.8%. On the basis of a price of €18.75 per share, the Company's market capitalisation is €71.3m.

Settlement and delivery of the new shares will take place on 12 July 2010, and continuous trading will begin on Tuesday 13 July 2010.

Carmat shares will be traded on the Alternext of NYSE Euronext Paris under the ISIN code **FR0010907956** and the ticker **ALCAR**.

**Not for direct or indirect distribution in the United States of America,  
Canada, Australia or Japan**

Marcello Conviti, CEO of CARMAT, comments: *“We are very pleased with the success of this offering, which makes this the largest such operation carried out on the Alternext of NYSE Euronext since the start of the year. Thanks to the funds raised, we expect to be able to carry out the first human implants of our total artificial heart from 2011, with a view to its commercialisation from 2013.”*

Jean-Claude Cadudal, Chairman of the CARMAT Board, and Professor Alain Carpentier, Chief Scientific Officer, conclude: *“The success of CARMAT’s IPO matches the major Public Health challenge that our total artificial heart aims to meet: to save thousands of lives by eventually making artificial heart implants a common surgical procedure. We would like to thank all our new shareholders, as well as our partners and staff, who have chosen to put their trust in us and to accompany us through this remarkable project.”*

**Financial intermediaries**



Co-Lead Manager



Listing Sponsor,  
Lead Manager and  
Bookrunner



Co-Lead Manager

**CARMAT, the world’s most advanced total artificial heart project**

**The only credible response for all cases of end-stage heart failure, which is a real public health issue:** CARMAT’s aim is to be able to provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

**The result of the combination of two types of expertise that are unique in the world:** the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of EADS, world aerospace leader.

**Imitating the natural heart:** given its size, its weight, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

**A project leader acknowledged at a European level:** with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by OSEO; a total of €33 million.

**Substantial involvement of prestigious shareholders:** Truffle Capital, the leading European venture capital firm, EADS and the Fondation Alain Carpentier.

For more information: [www.carmatsas.com](http://www.carmatsas.com)



**Not for direct or indirect distribution in the United States of America,  
Canada, Australia or Japan**

**Availability of the prospectus** – Copies of the Prospectus, consisting of the *Document de base* registration document registered with the AMF on 21 May 2010 under reference number I.10-037 and the *Note d'opération* granted visa n°10-180 on 14 June 2010, are available for free on request from CARMAT, *Direction Administrative et financière*, 36 avenue de l'Europe – CS 40533 – 78941 Vélizy Villacoublay Cedex, France, as well as on the AMF French stock market authorities' website ([www.amf-france.org](http://www.amf-france.org)) and CARMAT's website ([www.carmatsas.com/investisseurs](http://www.carmatsas.com/investisseurs)).

**Risk factors** - We would like to draw your attention to the “risk factors” section of the Prospectus registered by the AMF French stock market authorities. These risk factors are detailed in chapter 4 of the *Document de base* registration document and in section 2 of the *Note d'opération* relative to the operation.

**CARMAT**

**Marcello Conviti**

CEO

**Patrick Coulombier**

COO

Tel. : +33 (0)1 39 45 54 50

[investisseurs@carmatsas.com](mailto:investisseurs@carmatsas.com)

**DEXIA SECURITIES FRANCE**

**Listing Sponsor**

**Lead Manager and Bookrunner**

Jean-Michel Cabriot

Tel. : +33 (0)1 56 28 52 68

[jean-michel.cabriot@dexia-securities.fr](mailto:jean-michel.cabriot@dexia-securities.fr)

**NewCap.**

Financial Communication & Investor Relations

Axelle Vuillermet / Emmanuel Huynh

Tel. : +33 (0)1 44 71 94 94

[carmat@newcap.fr](mailto:carmat@newcap.fr)

**ALIZE RP** – Corporate Communication & Press Relations

Caroline Carmagnol

Tel.: +33 (0)6 64 18 99 59

[caroline@alizerp.com](mailto:caroline@alizerp.com)

Juliette Vandebroucq

Tel. : +33 (0)1 41 68 86 41

[juliette@alizerp.com](mailto:juliette@alizerp.com)

**ALCAR**  
**LISTED**  
**NYSE**  
**ALTERNEXT**

Name: **CARMAT**  
ISIN code: **FR0010907956**  
Ticker: **ALCAR**